{"id":1933,"date":"2018-05-23T10:00:29","date_gmt":"2018-05-23T10:00:29","guid":{"rendered":"https:\/\/d.ptpl.dev\/acarix\/acarix-appoints-senior-cardiovascular-medtech-marketing-expert-as-member-of-the-board-of-directors\/"},"modified":"2024-08-06T12:25:36","modified_gmt":"2024-08-06T12:25:36","slug":"acarix-appoints-senior-cardiovascular-medtech-marketing-expert-as-member-of-the-board-of-directors","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-appoints-senior-cardiovascular-medtech-marketing-expert-as-member-of-the-board-of-directors\/","title":{"rendered":"Acarix appoints senior cardiovascular medtech marketing expert as member of the Board of Directors"},"content":{"rendered":"
<\/strong><\/div>\n

Press release<\/p>\n

Malm\u00f6, May 23, 2018<\/p>\n

Acarix appoints senior cardiovascular medtech marketing expert as member of the Board of Directors<\/strong><\/p>\n

Acarix, developer of the CADScor\u00aeSystem for Coronary Artery Disease (CAD) risk assessment, today announced the appointment of a highly experienced marketing expert, Johanne Louise Br\u00e6ndgaard, as a member of the board of directors.<\/strong><\/p>\n

"We are delighted to welcome Johanne as member of the board. She has wide-ranging experience from the medtech sector in setting product, marketing and sales strategies specifically for the important European, US and APAC markets and an impressive network from the cardiovascular disease area. We expect that she will contribute immensely to achieving our goals with the accelerated market expansion activities." said Dr. Werner Braun, Chairman of the Board.<\/p>\n

\u00a0Johanne Louise Br\u00e6ndgaard has 13 years of experience from global sales, marketing and product management within the Medtech industry through positions in Cook Medical and Getinge. Johanne has a Master's degree in International Business Economics from Aalborg University in Denmark.<\/p>\n

Contacts:<\/strong><\/p>\n

Dr. Werner Braun, Chairman of the Board, E-mail info@acarix.com, Phone: +49 151 70 131\u00a0343<\/p>\n

Notes to editors:<\/strong><\/p>\n

Acarix was established in 2009, and since 2010 investors Sunstone Life Science Ventures (DK) and SEED Capital (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First North Premier in 2016 and has attracted a highly-experienced management team.<\/p>\n

The Acarix CADScor\u00aeSystem combines ultra-sensitive acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a portable device to provide a patient-specific score to non-invasively assess the risk for Coronary Artery Disease (CAD) in less than 10 minutes. The system has been clinically validated.<\/p>\n

See more at www.acarix.com<\/a>.<\/p>\n

Press photos: http:\/\/www.acarix.com\/about-us\/press-downloads\/press-photos\/<\/a><\/p>\n

Press release_New board member_Eng<\/a><\/p>\n

—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acarix AB via Globenewswire<\/em><\/p>\n

<\/div>\n